Cosmo Pharmaceuticals N.V. (CMOPF)

USD 55.0

(0.0%)

EBITDA Summary of Cosmo Pharmaceuticals N.V.

Cosmo Pharmaceuticals N.V.'s latest annual EBITDA in 2023 was 19.69 Million EUR , down -44.71% from previous year.
Cosmo Pharmaceuticals N.V.'s latest quarterly EBITDA in 2024 Q1 was 50.85 Million USD , up 1563.65% from previous quarter.
Cosmo Pharmaceuticals N.V. reported an annual EBITDA of 43.43 Million USD in 2022, up 107.76% from previous year.
Cosmo Pharmaceuticals N.V. reported an annual EBITDA of 20.9 Million USD in 2021, up 143.55% from previous year.
Cosmo Pharmaceuticals N.V. reported a quarterly EBITDA of 50.85 Million USD for 2024 Q1, up 1563.65% from previous quarter.
Cosmo Pharmaceuticals N.V. reported a quarterly EBITDA of 14.97 Million USD for 2023 Q2, up 96.78% from previous quarter.

Annual EBITDA Chart of Cosmo Pharmaceuticals N.V. (2023 - 2004)

Historical Annual EBITDA of Cosmo Pharmaceuticals N.V. (2023 - 2004)

Year	EBITDA	EBITDA Growth
2023	19.69 Million EUR	-44.71%
2022	43.43 Million USD	107.76%
2021	20.9 Million USD	143.55%
2020	7.83 Million USD	202.31%
2019	-7.02 Million USD	44.99%
2018	-15.25 Million EUR	-104.91%
2017	-7.44 Million EUR	-125.77%
2016	30.65 Million EUR	793.35%
2015	262.96 Million EUR	-90.95%
2014	117.85 Million EUR	57.63%
2013	22.65 Million EUR	-23.49%
2012	29.6 Million EUR	159.77%
2011	11.39 Million EUR	53.56%
2010	7.42 Million EUR	-0.05%
2009	7.42 Million EUR	-47.53%
2008	14.15 Million EUR	579.83%
2007	2.08 Million EUR	-45.92%
2006	3.85 Million EUR	53.33%
2005	2.98 Million EUR	1143.07%
2004	202 Thousand EUR	0.0%

Year	EBITDA	EBITDA Growth
2024 Q2	50.47 Million USD	0.0%
2024 Q1	50.85 Million USD	1563.65%
2023 Q2	14.97 Million USD	96.78%
2023 FY	- USD	-44.71%
2023 Q4	6.07 Million USD	103.02%
2023 Q3	2.99 Million USD	-80.01%
2023 Q1	7.61 Million USD	-72.51%
2022 FY	- USD	107.76%
2022 Q4	27.68 Million USD	115.22%
2022 Q3	12.86 Million USD	-13.87%
2022 Q2	14.93 Million USD	0.0%
2021 FY	- USD	143.55%
2021 Q4	16.82 Million USD	0.0%
2021 Q2	3.87 Million USD	0.0%
2020 Q2	46.03 Thousand USD	0.0%
2020 FY	- USD	202.31%
2020 Q4	8.58 Million USD	0.0%
2019 Q4	8.56 Million USD	0.0%
2019 FY	- USD	44.99%
2019 Q2	-17.22 Million USD	0.0%
2018 FY	- EUR	-104.91%
2017 FY	- EUR	-125.77%
2016 FY	- EUR	793.35%
2015 FY	- EUR	-90.95%
2014 FY	- EUR	57.63%
2013 FY	- EUR	-23.49%
2012 FY	- EUR	159.77%
2011 FY	- EUR	53.56%
2010 FY	- EUR	-0.05%
2009 FY	- EUR	-47.53%
2008 FY	- EUR	579.83%
2007 FY	- EUR	-45.92%
2006 FY	- EUR	53.33%
2005 FY	- EUR	1143.07%
2004 FY	- EUR	0.0%

Peer EBITDA Comparison of Cosmo Pharmaceuticals N.V.

Name	EBITDA	EBITDA Difference
AstraZeneca PLC	13.28 Billion USD	99.852%
Bristol-Myers Squibb Company PFD CONV 2	19.41 Billion USD	99.899%
CSPC Pharmaceutical Group Limited	1.14 Billion USD	98.284%
Clarus Therapeutics Holdings, Inc.	-39.7 Million USD	149.613%
Novartis AG	19.51 Billion USD	99.899%
PT Kalbe Farma Tbk.	288.13 Million USD	93.163%